High-throughput genomic profiling of tumor-infiltrating leukocytes
AM Newman, AA Alizadeh - Current opinion in immunology, 2016 - Elsevier
Highlights•Tumor infiltrating leukocytes (TILs) critically influence cancer clinical
outcomes.•Classical techniques for studying TILs have important limitations.•TILs can be …
outcomes.•Classical techniques for studying TILs have important limitations.•TILs can be …
A critical survey of deconvolution methods for separating cell types in complex tissues
S Mohammadi, N Zuckerman… - Proceedings of the …, 2016 - ieeexplore.ieee.org
Identifying properties and concentrations of components from an observed mixture, known
as deconvolution, is a fundamental problem in signal processing. It has diverse applications …
as deconvolution, is a fundamental problem in signal processing. It has diverse applications …
Bayesian sparse regression analysis documents the diversity of spinal inhibitory interneurons
Documenting the extent of cellular diversity is a critical step in defining the functional
organization of tissues and organs. To infer cell-type diversity from partial or incomplete …
organization of tissues and organs. To infer cell-type diversity from partial or incomplete …
Improving sensitivity of linear regression-based cell type-specific differential expression deconvolution with per-gene vs. global significance threshold
ER Glass, MG Dozmorov - BMC bioinformatics, 2016 - Springer
Background The goal of many human disease-oriented studies is to detect molecular
mechanisms different between healthy controls and patients. Yet, commonly used gene …
mechanisms different between healthy controls and patients. Yet, commonly used gene …
Exploiting gene-expression deconvolution to probe the genetics of the immune system
Y Steuerman, I Gat-Viks - PLoS Computational Biology, 2016 - journals.plos.org
Sequence variation can affect the physiological state of the immune system. Major
experimental efforts targeted at understanding the genetic control of the abundance of …
experimental efforts targeted at understanding the genetic control of the abundance of …
Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies
MWB Trotter - US Patent App. 15/101,866, 2016 - Google Patents
GYCBHHVIYOBLJB-UHFFFAOYSA-N C= C1CCC (C)(N2Cc3ccccc3C2= O) C (= O) N1. CN.
CN. O= C1CCC (N2C (= O) c3ccccc3C2= O) C (= O) N1 Chemical compound C= C1CCC …
CN. O= C1CCC (N2C (= O) c3ccccc3C2= O) C (= O) N1 Chemical compound C= C1CCC …
Characterization of the disease pathogenesis of Schimke immuno-osseous dysplasia
M Morimoto - 2016 - open.library.ubc.ca
Schimke immuno-osseous dysplasia (SIOD) is a rare autosomal recessive multisystemic
disorder characterized by disproportionate short stature due to skeletal dysplasia, renal …
disorder characterized by disproportionate short stature due to skeletal dysplasia, renal …
ImSig: A resource for the identification and quantification of immune signatures in blood and tissue transcriptomics data
The outcome of many diseases is commonly correlated with the immune response at the site
of pathology. The ability to monitor the status of the immune system in situ provides a …
of pathology. The ability to monitor the status of the immune system in situ provides a …
Factors associated with heterogeneity in microarray gene expression in peripheral blood mononuclear cells from large pedigrees
M Gallaugher, AJ Canty, AD Paterson - BMC proceedings, 2016 - Springer
Background Genome-wide microarray expression is a rich source of functional genomic
data. We examined evidence for differences in expression from peripheral blood …
data. We examined evidence for differences in expression from peripheral blood …
Statistical methods for Bayesian clinical trial design and DNA methylation deconvolution
MA Psioda - 2016 - search.proquest.com
We consider the Bayesian clinical trial design problem in situations where a historical trial is
available to inform the design and analysis of a future trial. Currently the FDA requires that …
available to inform the design and analysis of a future trial. Currently the FDA requires that …